Abera Bioscience (ABERA) Q1 2025 earnings summary

Executive summary

• Q1 2025 marked by significant progress in vaccine development, especially for influenza and pneumococcus candidates, with strong preclinical results and regulatory support for clinical advancement.

• Revenue for the quarter was 3,574 KSEK, mainly from grants, with a positive net result of 12 KSEK compared to -359 KSEK last year.

• Continued financial support from CEPI and UK Vaccine Network underpins ongoing R&D and operational stability.

• Focus remains on advancing vaccine candidates to early clinical phase for out-licensing.

• No commercial sales yet; all income derived from grants and project funding.

Financial highlights

• Net revenue: 3,574 KSEK (0 KSEK last year); all from grants and currency gains.

• Operating costs: -3,575 KSEK (vs. -2,629 KSEK), mainly R&D and personnel.

• Net income: 12 KSEK (vs. -359 KSEK year-over-year).

• Cash and equivalents: 5,501 KSEK at quarter-end (6,654 KSEK last year).

• Equity: 8,667 KSEK (9,267 KSEK last year); equity ratio 74% (79%).

Outlook and guidance

• Ambitious 2025 development plan, supported by CEPI and UK Vaccine Network funding.

• Clinical trials for lead pneumococcus candidate to begin once financing is secured.

• Ongoing grant inflows expected to cover operational costs through 2025.

• Focus on cost control and securing additional non-dilutive funding.

• Next financial reports scheduled for August and November 2025.